CLRB 2,16$
Seite 1 von 2 Neuester Beitrag: 04.09.24 11:34 | ||||
Eröffnet am: | 03.05.19 15:26 | von: Vassago | Anzahl Beiträge: | 31 |
Neuester Beitrag: | 04.09.24 11:34 | von: Highländer49 | Leser gesamt: | 12.505 |
Forum: | Börse | Leser heute: | 90 | |
Bewertet mit: | ||||
Seite: < | 2 > |
CRL131 Phase 2 Studie bald mit Ergebnissen
https://www.cellectar.com/product-pipeline
- Cash 13 Mio. $
- MK 11 Mio. $ (zum 31.12.18)
- Verlust 15 Mio. $ (in 2018)
- pro Quartal ~4 Mio. $
- Watchlist
https://investor.cellectar.com/press-releases/...-year-ended-december
- FDA Fast Track Designation für CRL 131
- Phase 1 Studiendaten für CRL 131
https://www.contractpharma.com/contents/...t-track-for-clr-131-in-mm/
https://investor.cellectar.com/press-releases/...-rate-in-cohort-6-of
10 Mio. $ Offering
https://investor.cellectar.com/press-releases/...-0-million-financing
https://www.nasdaq.com/de/symbol/clrb/real-time
20 Mio. $ Offering
https://investor.cellectar.com/press-releases/...ricing-of-20-million
Ich dachte die haben einen Geldspeicher wie Dagobert. Vermutlich nur Fakenews wie bei Donald.
Gruß Wilbär.
Offering
Verwunderlich das CLRB nicht stärker in Richtung des Angebotspreises vei 1,35$ fällt. Alles in allem sind das natürlich miese Konditionen. CLRB hatte gestern bei 2,77$ geschlossen und macht heute ein Offering zu 1,35$? 50% Discount?
https://seekingalpha.com/news/...ublic-offering-and-private-placement
Zeitpunkt: 25.04.21 20:25
Aktion: Löschung des Beitrages
Kommentar: Verdacht auf Spam-Nutzer
Preliminary Third Quarter 2023 Financial Highlights
Cash and Cash Equivalents:As of September 30, 2023, the company had cash and
cash equivalents of $19.0 million, compared to $19.9 million as of December 31, 2022.
During the third quarter, the company entered into a securities purchase agreement
with certain institutional investors for a private placement financing that is expected to
result in gross proceeds of up to $102.9 million, based upon achievement of certain
milestones. Current cash includes an initial funding of $22.2 million from the
transaction, net of commissions and fees. The company believes its cash on hand is
adequate to fund budgeted operations into the second quarter of 2024.
Research and Development Expense: R&D expense for the three months ended
September 30, 2023 was approximately $7.3 million, compared to approximately $5.4
million for the three months ended September 30, 2022. The overall increase in
research and development expense was primarily a result of an increase in WM pivotal
trial patient enrollment and expansion of the central nervous system lymphoma cohort
of the company’s Phase 2a basket trial in blood-b
Eigentlich waren die Studiendaten für Juni angekündigt worden. Nun werden sie um einen Monat auf den 24. Juli verschoben.
https://investor.cellectar.com/press-releases/...nion-leader-event-to